Taylor N S, Fox J G, Akopyants N S, Berg D E, Thompson N, Shames B, Yan L, Fontham E, Janney F, Hunter F M
Division of Comparative Medicine, Massachusetts Institute of Technology, Cambridge 02139, USA.
J Clin Microbiol. 1995 Apr;33(4):918-23. doi: 10.1128/jcm.33.4.918-923.1995.
The gastric pathogen Helicobacter pylori establishes long-term chronic infections that can lead to gastritis, peptic ulcers, and cancer. The species is so diverse that distinctly different strains are generally recovered from each patient. To better understand the dynamics of long-term carriage, we characterized H. pylori isolates from initial and follow-up biopsy specimens from a patient population at high risk of H. pylori infection and gastric cancer. Eighty-five isolates were obtained from 23 patients and were analyzed by genomic restriction enzyme analysis, arbitrarily primed PCR fingerprinting, (random amplified polymorphic DNA analysis), and/or restriction of specific PCR-amplified genes (restriction fragment length polymorphism analysis). A single strain was found in sequential biopsy specimens from 12 of 15 patients (80%) receiving sucralfate. In the remaining three patients treated with sucralfate, two strains were identified in two patients and three strains were identified in the third patient. In contrast, a single strain was found in sequential biopsy specimens from only three of eight patients (37%) receiving bismuth, metronidazole, and nitrofurantoin. Two strains were identified in five other patients receiving bismuth-antibiotic (63%). Immunoglobulin G antibodies to H. pylori were present in the sera of all patients. Thus, H. pylori colonization can persist for long periods (up to at least 4 years), despite high titers of immunoglobulin G antibodies in serum. Resistance to metronidazole was noted in some strains before and/or after treatment, but all strains remained susceptible to amoxicillin, tetracycline, and nitrofurantoin. We conclude that H. pylori genotypes, as measured by several sensitive DNA fingerprinting methods, can remain stable for years in vivo, despite the acquisition or loss of drug resistance, circulating antibody, or exposure to antibiotics or sucralfate.
胃部病原体幽门螺杆菌会引发长期的慢性感染,进而可能导致胃炎、消化性溃疡和癌症。该菌种具有高度多样性,通常从每位患者身上分离出的菌株都明显不同。为了更好地理解长期携带的动态过程,我们对来自幽门螺杆菌感染和胃癌高风险患者群体的初始及后续活检标本中的幽门螺杆菌分离株进行了特征分析。从23名患者身上获取了85株分离株,并通过基因组限制性酶切分析、任意引物PCR指纹图谱分析(随机扩增多态性DNA分析)和/或特定PCR扩增基因的限制性分析(限制性片段长度多态性分析)进行分析。在接受硫糖铝治疗的15名患者中,有12名(80%)的连续活检标本中发现了单一菌株。在其余3名接受硫糖铝治疗的患者中,有2名患者鉴定出2株菌株,第3名患者鉴定出3株菌株。相比之下,在接受铋剂、甲硝唑和呋喃妥因治疗的8名患者中,只有3名(37%)的连续活检标本中发现了单一菌株。在其他5名接受铋剂 - 抗生素治疗的患者中鉴定出了2株菌株(63%)。所有患者的血清中均存在抗幽门螺杆菌的免疫球蛋白G抗体。因此,尽管血清中免疫球蛋白G抗体滴度很高,但幽门螺杆菌定植仍可长期持续(至少长达4年)。在治疗前和/或治疗后,部分菌株出现了对甲硝唑的耐药性,但所有菌株对阿莫西林、四环素和呋喃妥因仍敏感。我们得出结论,通过几种敏感的DNA指纹图谱方法测定,幽门螺杆菌基因型在体内可多年保持稳定,尽管存在耐药性的获得或丧失、循环抗体,以及接触抗生素或硫糖铝的情况。